MHRA has granted conditional marketing authorization for CASGEVY™.
Vertex Pharmaceuticals and CRISPR Therapeutics announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and…